FY2025 EPS Estimates for Revvity Cut by Leerink Partnrs

Key Points

• Leerink Partners has lowered its FY2025 earnings per share estimate for Revvity to $4.86, down from $4.88, while the consensus estimate remains higher at $4.94.
• Various research firms have adjusted their price targets for Revvity, with Stifel Nicolaus setting a target of $110.00 and maintaining a "hold" rating.
• Revvity announced a quarterly dividend of $0.07 per share, with an ex-dividend date of October 17th, representing an annualized yield of 0.3%.

Revvity Inc. (NYSE:RVTY - Free Report) - Research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Revvity in a research report issued on Sunday, September 14th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of $4.86 for the year, down from their previous forecast of $4.88. The consensus estimate for Revvity's current full-year earnings is $4.94 per share. Leerink Partnrs also issued estimates for Revvity's Q2 2026 earnings at $1.28 EPS, Q4 2026 earnings at $1.64 EPS, FY2026 earnings at $5.40 EPS and FY2027 earnings at $6.06 EPS.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm had revenue of $720.28 million during the quarter, compared to analyst estimates of $711.26 million. During the same period last year, the business earned $1.22 earnings per share. The business's revenue was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS.

RVTY has been the topic of several other reports. Stifel Nicolaus decreased their target price on shares of Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a research report on Tuesday, July 29th. Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 3rd. Raymond James Financial restated an "outperform" rating and issued a $115.00 target price (down from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Bank of America dropped their target price on shares of Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Finally, Evercore ISI dropped their target price on shares of Revvity from $116.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Ten investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Revvity currently has a consensus rating of "Moderate Buy" and a consensus target price of $120.07.

Revvity Stock Performance

NYSE:RVTY traded down $1.08 during trading hours on Tuesday, reaching $86.68. The company had a trading volume of 3,530,393 shares, compared to its average volume of 1,176,729. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. Revvity has a 52 week low of $81.36 and a 52 week high of $129.50. The firm has a market cap of $10.06 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 2.36 and a beta of 0.94. The firm's 50 day moving average price is $90.03 and its 200-day moving average price is $95.31.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity's payout ratio is 11.86%.

Hedge Funds Weigh In On Revvity

A number of institutional investors have recently bought and sold shares of RVTY. Ameriprise Financial Inc. raised its stake in Revvity by 40.4% during the fourth quarter. Ameriprise Financial Inc. now owns 74,252 shares of the company's stock worth $8,287,000 after purchasing an additional 21,380 shares during the period. Cetera Investment Advisers raised its stake in Revvity by 17.2% during the fourth quarter. Cetera Investment Advisers now owns 5,786 shares of the company's stock worth $646,000 after purchasing an additional 848 shares during the period. Focus Partners Wealth raised its stake in Revvity by 139.7% during the fourth quarter. Focus Partners Wealth now owns 6,217 shares of the company's stock worth $694,000 after purchasing an additional 3,623 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Revvity by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,032 shares of the company's stock valued at $1,231,000 after acquiring an additional 435 shares during the period. Finally, Nuveen Asset Management LLC raised its stake in shares of Revvity by 0.3% in the 4th quarter. Nuveen Asset Management LLC now owns 262,823 shares of the company's stock valued at $29,334,000 after acquiring an additional 826 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.